Millendo Therapeutics, Inc.
MLND · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Market Cap | – | $2,691 | $6,159 | $820 |
| - Cash | $30,268 | $38,174 | $62,478 | $73,286 |
| + Debt | $8,142 | $2,672 | $4,522 | $572 |
| Enterprise Value | – | -$32,811 | -$51,797 | -$71,894 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $0 | -$35,302 | -$44,554 | -$27,026 |
| % Margin | – | – | – | – |
| Net Income | -$41,843 | -$36,406 | -$44,568 | -$27,192 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.5 | -28.95 | -48.77 | -263.65 |
| % Growth | 94.8% | 40.6% | 81.5% | – |
| Operating Cash Flow | $0 | -$30,435 | -$41,222 | -$23,647 |
| Capital Expenditures | -$435 | -$26 | -$397 | -$36 |
| Free Cash Flow | -$435 | -$30,461 | -$41,619 | -$23,683 |